Endocrine Abstracts

Contents

• Oral Communications
• • Section
  • • Novel phenotypic and exonic variants for Neuroendocrine Neoplams: a UK Biobank study

      ea0096oc1
    • Interim analysis of Lantana: A phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours (NCT05178693)

      ea0096oc2
    • Factors affecting overall survival after surgery for lung neuroendocrine tumours: A single centre series

      ea0096oc3
• Poster Presentations
• • Section
  • • Development of a mobile app for patients with neuroendocrine neoplasm

      ea0096p1
    • The Global leadership into malnutrition criteria reveals a high percentage of malnutrition which influences overall survival in patients with gastroenteropancreatic neuroendocrine tumours using somatostatin analogues

      ea0096p2
    • High prevalence of deficiencies in fat-soluble vitamins, minerals and trace elements but no relation with malnutrition in patients with gastroenteropancreatic neuroendocrine tumours using somatostatin analogue's

      ea0096p3
    • Is a patient's bmi representative of their body composition in neuroendocrine tumours?

      ea0096p4
    • Investigation of the utility of [⁶⁸Ga]Ga-DOTA-TATE PET/CT scanning in patients with Multiple Endocrine Neoplasia Type 1 (MEN1) with suspected pancreatic neuroendocrine tumours

      ea0096p5
    • Evaluation by patient questionnaire of a dedicated NET dietitian service provided to Neuroendocrine Tumour patients

      ea0096p6
    • Findings of a retrospective data analysis on outcome of temozolomide singe agent and temozolomide/capecitabine in patients with gastroenteropancreatic neuroendocrine neoplasms (gep-nen) in the european neuroendocrine tumour centre of excellence at the beatson west of scotland cancer centre, glasgow

      ea0096p7
    • Audit of glycaemic control and assessment in Pancreatic Neuroendocrine Tumours (pNETS) in Sheffield NET Centre ENETS Centre of Excellence

      ea0096p8
    • Evaluating the impact and patient experience of a transition from urine to plasma 5-HIAA measurement

      ea0096p9
    • A prrt patient experience survey - what really matters to patients?

      ea0096p10
    • How gallstones can affect the course of PRRT

      ea0096p11
    • Co-production of Patient Information: a model for future practice?

      ea0096p12
    • Neuroendocrine cancer: an ideal patient care pathway - addressing inequities in diagnosis, care and support

      ea0096p13
    • Pituitary disease in MEN1: follow up of patients in Northern Ireland

      ea0096p14
    • Alternative splicing and its role in the pathology of Pancreatic and Small Intestine Neuroendocrine tumours

      ea0096p15
    • Sporadic neuroendocrine neoplasms in patients aged 18-40 years in a tertiary referral centre

      ea0096p16
    • Bridging the gap between neuroendocrine tumour service and nuclear medicine, a new cns role?

      ea0096p17
    • Feasibility of home parenteral nutrition in patients with intestinal failure due to small intestinal neuroendocrine tumours: a systematic review

      ea0096p18
    • Case series of Carcinoid heart presentation with Ovarian neuroendocrine tumour in a tertiary Centre

      ea0096p19
    • Carcinoid heart disease in patients unfit for surgery: a case series of medically managed patients

      ea0096p20
    • The frequency of carcinoid heart disease in our neuroendocrine tumour cohort: a tertiary centre experience

      ea0096p21
    • Successes and challenges in the combined neuroendocrine tumour and carcinoid heart disease service university hospitals birmingham: a neuroendocrine tumour clinical specialist nurse perspective

      ea0096p22
    • Reasons patients with carcinoid heart disease are deemed unfit for surgery: our tertiary centre experience

      ea0096p23
    • Painful cutaneous metastases in well differentiated bronchial neuroendocrine tumour (NET); could serotonin be the guilty molecule?

      ea0096p24
    • Sequencing of treatment in G1-2 pancreatic neuroendocrine tumour - a case study

      ea0096p25
    • Case report: a rectal neuroendocrine tumour with dynamic grade and clinical behaviour

      ea0096p26
    • Which cancer? Clinical decision making in a case of concurrent metastatic neuroendocrine tumour and breast cancer

      ea0096p27